zurück

Fenfluramine (new indication: Lennox-Gastaut syndrome as an add-on therapy for patients aged ≥ 2 years)

 

Subject:

  • Active Substance: Fenfluramine
  • Name: Fintepla®
  • Therapeutic area: Lennox-Gastaut syndrome
  • Pharmaceutical company: Zogenix GmbH

 

Time table:

  • Start: 15.02.2023
  • Publication of assessment: 15.05.2023
  • End of public hearing: 05.06.2023
  • Final decision by G-BA: beginning of August 2023

 

Comparative therapy:

  • No comparative therapy due to orphan drug designation